Shahrekord University of Medical Sciences Journal of Herbmed Pharmacology 2345-5004 11 1 2022 01 01 Chemical constituents and evidence-based pharmacological properties of Physalis peruviana L.: An overview 35 47 10.34172/jhp.2022.04 EN Félicien Mushagalusa Kasali https://orcid.org/0000-0001-5956-2110 Naasson Tuyiringire https://orcid.org/0000-0002-3347-2237 Emanuel L Peter https://orcid.org/0000-0002-8162-4784 Lucrèce Y . Ahovegbe https://orcid.org/0000-0003-4405-5954 Muhammad Shaiq Ali https://orcid.org/0000-0002-3337-2818 Jonans Tusiimire https://orcid.org/0000-0002-5831-1499 Patrick Engeu Ogwang https://orcid.org/0000-0002-2119-4110 Justin Ntokamunda Kadima https://orcid.org/0000-0003-0395-7935 Amon Ganafa Agaba https://orcid.org/0000-0003-1411-6517 Journal Article 10.34172/jhp.2022.04 2020 12 16 2021 01 21 Physalis peruviana L. is among plant species possessing evident nutritional, nutraceutical, and commercial interests. This review highlights the complexity of the chemical composition supporting the multiple pharmacotherapeutic indications and dietary values of this plant through evidence-based studies from Google Scholar, PubMed/Medline, SciFinder, Science Direct, Scopus, the Wiley online library, and Web of Science. The literature mentions at least 40 compounds isolated from different parts; others are still under investigation. High yields in carotenoids, amino acids, minerals, vitamin C, vitamin E, and essential fatty acids have healthy nutritional benefits. Various phytoconstituents, particularly withanolides, exhibit anti-carcinogenic, anti-inflammatory, and antidiabetic potentials, as well as cardiovascular and liver protective effects. Prospective studies reveal that the leaves would also provide various beneficial bioactive chemicals worth being isolated. However, clinical evidence-based studies are seldom. Therefore, adequate pharmaceutical formulations and more in-depth controlled clinical trials are needed to fill the gap.